Impel Pharmaceuticals Inc.
Impel Pharmaceuticals Inc. (IMPL) Revenue
Annual & quarterly revenue history · segment & region breakdown
IMPL · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsImpel Pharmaceuticals Inc. trailing twelve-month (TTM) revenue is $0.02B, an increase of 1794.01% year-over-year from $0.01B in FY2022.
Revenue trend
2022 – 2019 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2022-12-31 | $0.01B | +$0.01B | +1794.01% |
| 2021-12-31 | $0.00B | +$0.00B | — |
| 2020-12-31 | $0.00B | +$0.00B | — |
| 2019-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Impel Pharmaceuticals Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Impel Pharmaceuticals Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Impel Pharmaceuticals Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
IMPL revenue · 4 questionsIMPL's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 1794.01% year-over-year from $0.01B in FY2022.
▸ Source: FMP · Impel Pharmaceuticals Inc. SEC filings · GAAP · Impel Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026